NEW DATA SUGGESTS IMPROVED TUMOR RESPONSE FOR THE COMBINATION OF AZIXA® AND IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER
28. Juni 2016 02:30 ET
|
Immune Pharmaceuticals Inc
NEW DATA SUGGESTS IMPROVED TUMOR RESPONSE FOR THE COMBINATION OF AZIXA AND
IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER
Immune Pharmaceuticals Files New Provisional Patent...
Immune Pharmaceuticals' Common Stock Approved for Trading on NASDAQ OMX First North Premier
26. November 2013 00:38 ET
|
Immune Pharmaceuticals Inc
TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 26, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that its common stock has...
Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
20. November 2013 03:14 ET
|
Immune Pharmaceuticals Inc
GAIN ON MERGER TRANSACTION DRIVES INCREASE IN STOCKHOLDERS' EQUITY TO $7.8 MILLION
TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 20, 2013 /PRNewswire/ -- Immune Pharmaceuticals...
Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
01. November 2013 02:08 ET
|
Immune Pharmaceuticals Inc
TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 1, 2013 -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that it has appointed Erik Penser...
New Data Supports Clinical Rationale for Bertilimumab in Ulcerative Colitis
16. Oktober 2013 00:43 ET
|
Immune Pharmaceuticals Inc
Phase II Trial to Focus on Moderate to Severe UC Patients with Eotaxin-1 Biomarker
TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Oct. 16, 2013 /PRNewswire/ -- Immune Pharmaceuticals...
Immune Pharmaceuticals Announces Changes to its Board of Directors
15. Oktober 2013 01:04 ET
|
Immune Pharmaceuticals Inc
New Members Provide strong financing and operating experience
TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Oct. 15, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX...
IMMUNE Pharmaceuticals Inc. to Present at 12th Annual BIO Investor Forum
03. Oktober 2013 00:37 ET
|
Immune Pharmaceuticals Inc
TARRYTOWN, N.Y., Oct. 3, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Dr. Daniel G. Teper, Company Chairman and CEO,...
Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States
30. September 2013 03:16 ET
|
Immune Pharmaceuticals Inc
Company to Transfer Swedish Listing to NASDAQ OMX First North Premier
TARRYTOWN, N.Y., Sept. 30, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange and OTCQX: IMNP)...
Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform
23. September 2013 00:57 ET
|
Immune Pharmaceuticals Inc
TARRYTOWN, N.Y., Sept. 23, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: IMNP, formerly EPCTD) announced today that effective September 23, 2013...
Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City September 8-10th, 2013
04. September 2013 03:07 ET
|
Immune Pharmaceuticals Inc
TARRYTOWN, N.Y., Sept. 4, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) today announced it will be featured as a presenting company at the...